Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 2
Tests tamoxifen with ruxolitinib in people with myelofibrosis
Tests tamoxifen added to ruxolitinib in adults with myelofibrosis, a blood disease.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 14 people, planned
- Started
- 1 Nov 2025
- Expected to end
- 1 Mar 2027
- Type of study
- Interventional
- Record updated
- 11 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with myelofibrosis. It tests tamoxifen together with ruxolitinib.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Netherlands
- Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests tamoxifen with ruxolitinib in people with myelofibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 November 2025